Fig. 2.

Small animal ⁸⁹Zr-DFO-6E11 PET/CT in HCC827 tumour-bearing mice. a Representative PET/CT images of the same mouse at 4, 24, 72, and 144 h post-injection of ⁸⁹Zr-DFO-6E11 illustrating targeting to lymphoid tissue and tumour. b Image-derived biodistribution over the imaging time-course in major organs. c Average (mean) and maximum (max) tumour uptake of ⁸⁹Zr-DFO-6E11 expressed as %ID/g at 4, 24, 72, and 144 h post-injection. d Tumour-to-heart and tumour-to-muscle ratios of the mean ⁸⁹Zr-DFO-6E11 uptake over the imaging time-course. e Ex vivo biodistribution measured by gamma counting of ⁸⁹Zr-DFO-6E11 after the last imaging session 144 h post-injection. N = 8 for all time points except 144 h, where N = 3. Data are presented as mean ± SEM. %ID/g = % injected dose per gram tissue. ALN, axillary lymph node; CLN, cervical lymph node